Your browser doesn't support javascript.
loading
The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I-Associated Peptides.
Bedran, Georges; Gasser, Hans-Christof; Weke, Kenneth; Wang, Tongjie; Bedran, Dominika; Laird, Alexander; Battail, Christophe; Zanzotto, Fabio Massimo; Pesquita, Catia; Axelson, Håkan; Rajan, Ajitha; Harrison, David J; Palkowski, Aleksander; Pawlik, Maciej; Parys, Maciej; O'Neill, J Robert; Brennan, Paul M; Symeonides, Stefan N; Goodlett, David R; Litchfield, Kevin; Fahraeus, Robin; Hupp, Ted R; Kote, Sachin; Alfaro, Javier A.
Afiliação
  • Bedran G; International Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.
  • Gasser HC; School of Informatics, University of Edinburgh, Edinburgh, United Kingdom.
  • Weke K; International Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.
  • Wang T; School of Informatics, University of Edinburgh, Edinburgh, United Kingdom.
  • Bedran D; International Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.
  • Laird A; Urology Department, Western General Hospital, NHS Lothian, Edinburgh, United Kingdom.
  • Battail C; Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.
  • Zanzotto FM; CEA, Grenoble Alpes University, INSERM, IRIG, Biosciences and Bioengineering for Health Laboratory (BGE) - UA13 INSERM-CEA-UGA, Grenoble, France.
  • Pesquita C; Department of Enterprise Engineering, University of Rome "Tor Vergata", Rome, Italy.
  • Axelson H; LASIGE, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal.
  • Rajan A; Division of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.
  • Harrison DJ; School of Informatics, University of Edinburgh, Edinburgh, United Kingdom.
  • Palkowski A; School of Medicine, University of St Andrews, St Andrews, United Kingdom.
  • Pawlik M; International Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.
  • Parys M; Academic Computer Centre CYFRONET, AGH University of Science and Technology, Cracow, Poland.
  • O'Neill JR; Royal (Dick) School of Veterinary Studies and The Roslin Institute, University of Edinburgh, Edinburgh, United Kingdom.
  • Brennan PM; Cambridge Oesophagogastric Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
  • Symeonides SN; Translational Neurosurgery, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom.
  • Goodlett DR; Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, United Kingdom.
  • Litchfield K; International Centre for Cancer Vaccine Science, University of Gdansk, Gdansk, Poland.
  • Fahraeus R; Department of Biochemistry and Microbiology, University of Victoria, Victoria, Canada.
  • Hupp TR; University of Victoria Genome BC Proteome Centre, Victoria, Canada.
  • Kote S; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, United Kingdom.
  • Alfaro JA; Tumour Immunogenomics and Immunosurveillance Laboratory, University College London Cancer Institute, London, United Kingdom.
Cancer Immunol Res ; 11(6): 747-762, 2023 06 02.
Article em En | MEDLINE | ID: mdl-36961404
ABSTRACT
Tumor antigens can emerge through multiple mechanisms, including translation of noncoding genomic regions. This noncanonical category of tumor antigens has recently gained attention; however, our understanding of how they recur within and between cancer types is still in its infancy. Therefore, we developed a proteogenomic pipeline based on deep learning de novo mass spectrometry (MS) to enable the discovery of noncanonical MHC class I-associated peptides (ncMAP) from noncoding regions. Considering that the emergence of tumor antigens can also involve posttranslational modifications (PTM), we included an open search component in our pipeline. Leveraging the wealth of MS-based immunopeptidomics, we analyzed data from 26 MHC class I immunopeptidomic studies across 11 different cancer types. We validated the de novo identified ncMAPs, along with the most abundant PTMs, using spectral matching and controlled their FDR to 1%. The noncanonical presentation appeared to be 5 times enriched for the A03 HLA supertype, with a projected population coverage of 55%. The data reveal an atlas of 8,601 ncMAPs with varying levels of cancer selectivity and suggest 17 cancer-selective ncMAPs as attractive therapeutic targets according to a stringent cutoff. In summary, the combination of the open-source pipeline and the atlas of ncMAPs reported herein could facilitate the identification and screening of ncMAPs as targets for T-cell therapies or vaccine development.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígenos de Histocompatibilidade Classe I / Neoplasias Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Polônia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antígenos de Histocompatibilidade Classe I / Neoplasias Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: Cancer Immunol Res Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Polônia